0001062993-23-015315.txt : 20230725 0001062993-23-015315.hdr.sgml : 20230725 20230725172742 ACCESSION NUMBER: 0001062993-23-015315 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230721 FILED AS OF DATE: 20230725 DATE AS OF CHANGE: 20230725 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kummeth Charles R. CENTRAL INDEX KEY: 0001534980 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 231109541 MAIL ADDRESS: STREET 1: 425 MARTINGALE ROAD STREET 2: SUITE 1000 CITY: SCHAUMBURG STATE: IL ZIP: 60173-2213 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2023-07-21 0000842023 BIO-TECHNE Corp TECH 0001534980 Kummeth Charles R. 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413 1 1 0 0 Chief Executive Officer 1 Common Stock 2023-07-21 4 S 0 80000 88.3628 D 1258766 D Common Stock 400 I By Step-Son Common Stock 400 I By Step-Daughter Stock Options (Right to Buy) 31.2625 2024-08-09 Common Stock 779084 779084 D Stock Options (Right to Buy) 44.33 2025-08-08 Common Stock 361336 361336 D Stock Options (Right to Buy) 44.33 2025-08-08 Common Stock 240888 240888 D Stock Options (Right to Buy) 47.6025 2026-08-07 Common Stock 342900 342900 D Restricted Stock Units Common Stock 52900 52900 D Stock Options (Right to Buy) 47.6025 2026-08-07 Common Stock 228600 228600 D Restricted Stock Units Common Stock 51516 51516 D Stock Options (Right to Buy) 66.9675 2027-08-05 Common Stock 299768 299768 D Stock Options (Right to Buy) 66.9675 2027-08-05 Common Stock 153180 153180 D Stock Options (Right to Buy) 66.9675 2027-08-05 Common Stock 66600 66600 D Stock Options (Right to Buy) 66.9675 2027-08-05 Common Stock 66600 66600 D Restricted Stock Units Common Stock 32064 32064 D Stock Options (Right to Buy) 120.455 2028-08-06 Common Stock 125260 125260 D Stock Options (Right to Buy) 120.455 2028-08-06 Common Stock 83504 83504 D Stock Options (Right to Buy) 94.52 2029-08-15 Common Stock 1200000 1200000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.95 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. Fully exercisable. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 17,632 shares vest on each of 8/15/2023 and 8/15/2025, and 17,636 shares vest on 8/15/2024. Options to purchase 57,152 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 57,148 shares vest on each of 8/7/2022 and 8/7/2023. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 38,292 shares vest on 8/5/21 and options to purchase 38,296 shares vest on each of 8/5/22, 8/5/23 and 8/5/24. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. Options to purchase 22,200 shares vest on each of 8/5/21, 8/5/22 and 8/5/23. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 20,876 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. 600,000 options vest in full or in part on 7/1/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator), and 600,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). /s/ Andrew Nick, as Attorney-in-Fact pursuant to Power of Attorney previously filed. 2023-07-25